MacroGenics (NASDAQ:MGNX – Get Rating) had its target price boosted by equities researchers at JMP Securities from $8.00 to $10.00 in a research note issued on Thursday, The Fly reports. JMP Securities’ price objective indicates a potential upside of 51.98% from the company’s previous close.
Several other research analysts also recently weighed in on the company. Stifel Nicolaus increased their price target on MacroGenics from $15.00 to $17.00 in a research note on Thursday, March 9th. Guggenheim reissued a “neutral” rating on shares of MacroGenics in a report on Friday, March 17th. StockNews.com assumed coverage on MacroGenics in a research report on Thursday, March 16th. They set a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of MacroGenics in a research note on Monday, April 3rd. Finally, Citigroup increased their price target on MacroGenics from $7.00 to $8.00 in a report on Monday, March 20th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.
MacroGenics Stock Down 4.2 %
NASDAQ MGNX opened at $6.58 on Thursday. MacroGenics has a 12-month low of $2.13 and a 12-month high of $7.90. The firm’s 50 day moving average is $6.76 and its 200-day moving average is $6.24. The company has a market capitalization of $406.91 million, a PE ratio of -3.39 and a beta of 2.00.
Insider Buying and Selling at MacroGenics
In other MacroGenics news, major shareholder Target N. V. Biotech acquired 500,000 shares of the stock in a transaction that occurred on Tuesday, February 14th. The stock was bought at an average cost of $5.07 per share, for a total transaction of $2,535,000.00. Following the completion of the transaction, the insider now owns 9,579,963 shares of the company’s stock, valued at approximately $48,570,412.41. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Jeffrey Stuart Peters sold 5,372 shares of MacroGenics stock in a transaction on Friday, March 10th. The stock was sold at an average price of $6.03, for a total value of $32,393.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Target N. V. Biotech purchased 500,000 shares of the business’s stock in a transaction on Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. Following the completion of the purchase, the insider now owns 9,579,963 shares of the company’s stock, valued at $48,570,412.41. The disclosure for this purchase can be found here. Insiders own 7.90% of the company’s stock.
Hedge Funds Weigh In On MacroGenics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in MacroGenics in the 1st quarter valued at approximately $27,000. Point72 Middle East FZE purchased a new stake in shares of MacroGenics during the 4th quarter worth approximately $28,000. Nisa Investment Advisors LLC boosted its stake in shares of MacroGenics by 692.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,150 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 4,500 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of MacroGenics by 228.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 9,281 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 6,451 shares in the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of MacroGenics during the 4th quarter worth approximately $77,000. Hedge funds and other institutional investors own 93.63% of the company’s stock.
MacroGenics Company Profile
MacroGenics, Inc is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.
- Get a free copy of the StockNews.com research report on MacroGenics (MGNX)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.